BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)

European Journal of Cancer

Volumn 50, Issue 12, 2014, Pages 2090-2098

  Ruscito, I ^a,b   Dimitrova, D ^a   Vasconcelos, I ^a   Gellhaus, K ^c   Schwachula, T ^c   Bellati, F ^b   Zeillinger, R ^d   Benedetti Panici, P ^b   Vergote, I ^e   Mahner, S ^f   Cacsire Tong, D ^c   Concin, N ^g   Darb Esfahani, S ^a   Lambrechts, S ^e   Sehouli, J ^a   Olek, S ^c   Braicu, E I ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Ivana Türbachova Laboratory for Epigenetics Epiontis GMBH   (Germany)

^d UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

BRCA1; Gene promoter; High grade serous ovarian cancer; Methylation; Prognosis

Indexed keywords

BRCA1 PROTEIN; DNA; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DNA EXTRACTION; DNA METHYLATION; EXON; FEMALE; FOLLOW UP; FROZEN SECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION;

BRCA1; GENE PROMOTER; HIGH GRADE SEROUS OVARIAN CANCER; METHYLATION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA METHYLATION; FEMALE; GENE SILENCING; GENES, BRCA1; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84904036648     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.05.001     Document Type: Article

References (31)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. A. du Bois, A. Reuss, and E. Pujade-Lauraine et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials - by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Can- cers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
3. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
4. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
5. D.N. Mancini, D.I. Rodenhiser, P.J. Ainsworth, F.P. O'Malley, S.M. Singh, and W. Xing et al. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site Oncogene 16 9 1998 1161 1169
6. A. Catteau, W.H. Harris, C.F. Xu, and E. Solomon Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics Oncogene 18 11 1999 1957 1965
7. T. Bianco, G. Chenevix-Trench, D.C. Walsh, J.E. Cooper, and A. Dobrovic Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer Carcinogenesis 21 2 2000 147 151
8. M. Esteller, J.M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, and E. Lerma et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 7 2000 564 569
9. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, and S. Narod et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Cancer Res 60 19 2000 5329 5333
10. C. Wang, A. Horiuchi, T. Imai, S. Ohira, K. Itoh, and T. Nikaido et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene J Pathol 202 2 2004 215 223
11. C.B. Wilcox, B.E. Baysal, H.H. Gallion, M.A. Strange, and J.A. DeLoia High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors Cancer Genet Cytogenet 159 2 2005 114 122
12. J.Z. Press, A. De Luca, N. Boyd, S. Young, A. Troussard, and Y. Ridge et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities BMC Cancer 8 2008 17
13. R. Chekerov, I. Braicu, D.C. Castillo-Tong, R. Richter, and I. Cadron et al. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD Int J Gynecol Cancer 23 2 2013 268 275
14. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin, and S.B. Baylin Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci U S A 93 18 1996 9821 9826
15. J. Sehouli, D. Könsgen, A. Mustea, G. Oskay-Ozcelik, I. Katsares, and H. Weidemann et al. "IMO" - intraoperative mapping of ovarian cancer Zentralbl Gynakol 125 3-4 2003 129 135
16. K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, and B.Y. Karlan et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JAMA 307 4 2012 382 390
17. I. Türbachova, T. Schwachula, I. Vasconcelos, A. Mustea, T. Baldinger, and K.A. Jones et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns Epigenetics 8 11 2013 1226 1235
18. A. Mukhopadhyay, A. Elattar, A. Cerbinskaite, S.J. Wilkinson, Y. Drew, and S. Kyle et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors Clin Cancer Res 16 8 2010 2344 2351
19. K.K. Zorn PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check Oncology (Williston Park) 26 2 2012 128 136
20. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 7418 2012 61 70
21. T.B. Miranda, and P.A. Jones DNA methylation: the nuts and bolts of repression J Cell Physiol 213 2 2007 384 390
22. E. Senturk, S. Cohen, P.R. Dottino, and J.A. Martignetti A critical re-appraisal of BRCA1 methylation studies in ovarian cancer Gynecol Oncol 119 2 2010 376 383
23. K.P. Suijkerbuijk, X. Pan, E. van der Wall, P.J. van Diest, and M. Vooijs Comparison of different promoter methylation assays in breast cancer Anal Cell Pathol (Amst) 33 3 2010 133 141
24. S.A. Jackson, A.A. Davis, J. Li, N. Yi, S.R. McCormick, and C. Grant et al. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2 Cancer 120 10 2014 1557 1564
25. J.M. Cunningham, M.S. Cicek, N.B. Larson, J. Davila, C. Wang, and M.C. Larson et al. Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status Sci Rep 7 4 2014 4026
26. J.W. Chiang, B.Y. Karlan, L. Cass, and R.L. Baldwin BRCA1 promoter methylation predicts adverse ovarian cancer prognosis Gynecol Oncol 101 3 2006 403 410
27. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, and A.K. Sood et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JAMA 306 14 2011 1557 1565
28. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 2003 2187 2195
29. D. Thompson, and D. Easton Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position Cancer Epidemiol Biomarkers Prev 11 4 2002 329 336
30. H.A. Risch, J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley, and I. Fan et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 23 2006 1694 1706
31. T. Hansmann, G. Pliushch, M. Leubner, P. Kroll, D. Endt, and A. Gehrig et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer Hum Mol Genet 21 21 2012 4669 4679